American Society of Hematology

Fig. 4.

$Fig. 4. SIVenv- and SIVgag/pol-specific CD8+ pCTL frequencies in PBMC samples from rhesus macaques following SIVmac239 infection. / SIV infection alone (A); SIV infection and a 28-day course of PMPA chemotherapy (B); SIV infection, PMPA chemotherapy, and infusions with autologous unfractionated PBMCs (C); SIV infection, PMPA chemotherapy, and infusions with anti-CD3/CD28-stimulated and -expanded autologous CD4+ T cells (D). Sequential Flu-MP–specific CD8+ pCTL frequencies in PBMC samples following SIVmac239 infection alone (E); SIV infection, PMPA chemotherapy, and infusions with autologous unfractionated PBMCs (F); SIV infection, PMPA chemotherapy, and infusions with anti-CD3/CD28-stimulated and -expanded autologous CD4+ T cells (G).$

SIVenv- and SIVgag/pol-specific CD8⁺ pCTL frequencies in PBMC samples from rhesus macaques following SIVmac239 infection.

SIV infection alone (A); SIV infection and a 28-day course of PMPA chemotherapy (B); SIV infection, PMPA chemotherapy, and infusions with autologous unfractionated PBMCs (C); SIV infection, PMPA chemotherapy, and infusions with anti-CD3/CD28-stimulated and -expanded autologous CD4⁺ T cells (D). Sequential Flu-MP–specific CD8⁺ pCTL frequencies in PBMC samples following SIVmac239 infection alone (E); SIV infection, PMPA chemotherapy, and infusions with autologous unfractionated PBMCs (F); SIV infection, PMPA chemotherapy, and infusions with anti-CD3/CD28-stimulated and -expanded autologous CD4⁺ T cells (G).

This Feature Is Available To Subscribers Only